Aptose Biosciences Inc (APTO)

[dcaf7]

Published today in Targeted Therapies in Oncology.
Another noncovalent BTK inhibitor, CG-806 (luxeptinib), is undergoing evaluation in early-phase clinical trials for patients with relapsed/refractory (R/R) hematologic malignancies, including MCL, chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma. Investigators demonstrated that the agent disrupts B-cell receptor signaling and induces metabolic reprogramming and apoptosis in MCL. The investigators noted that targeting BCL2 using CG-806 warrants further exploration.7
Refreshed my memory briefly reading paper referenced as 7. Authors call Lux as dual BTK/SYK inhibitor. It looks like SYK inhibition provides Venetoclax-like effect although combination of Lux + Venetoclax is synergistic.